A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Clinical trial NCT07483450 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07483450
Sponsor: Hoffmann-La Roche
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Relapsing Multiple Sclerosis Primary Progressive Multiple Sclerosis

Start date: 2025-07-04
Primary completion: 2027-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.